Eric K. Singhi: FDA Oncology approves amivantamab and chemo for EGFR and NSCLC

Eric K. Singhi shared a post on X:

“FDA Oncology approves amivantamab and chemo for EGFR+ mNSCLC after TKI progression per phase 3 MARIPOSA-2 study:

• •  PFS: 6.3 v 4.2 mos (HR 0.48)
  •  ORR: 53% v 29%
  • No OS difference at interim (HR 0.73)
  • AEs: rash, IRR, nail toxicity, stomatitis.”

Source: Eric K. Singhi/X

Dr. Eric K. Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.